Cerus to Present at the Oppenheimer 22nd Annual Healthcare Conference on December 14, 2011

Published on Wednesday, 07 December 2011 08:40 Written by TradersHuddle Staff

CONCORD, Calif.-( Business Wire )-

Cerus Corporation (NASDAQ:CERS) announced today that William “Obi” Greenman, president and chief executive officer, is scheduled to present a corporate update at the Oppenheimer 22^nd Annual Healthcare Conference in New York at 3:20 PM EDT on Wednesday, December 14, 2011.

A live webcast of the presentation will be available from the Investor Relations page of the Cerus web site at http://investor.cerus.com. A replay will be available for approximately two weeks following the completion of the event.

ABOUT CERUS

Cerus Corporation is a biomedical products company focused on commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT system is designed to reduce the risk of transfusion-transmitted diseases by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action enables INTERCEPT treatment to inactivate established transfusion threats, such as hepatitis B and C, HIV, West Nile virus and bacteria, and is designed to inactivate emerging pathogens such as influenza, malaria and dengue. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world. The INTERCEPT red blood cell system is in clinical development. See http://www.cerus.com for more information.

INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.

Cerus CorporationLainie Corten, 925-288-6319Director, Global Communications & Marketing